Anhui Weiming Damu Biopharmaceutical

Anhui Weiming Damu Biopharmaceutical is a Chinese biotechnology company based in Hefei, Anhui, specializing in the development of therapeutic biologics. As a subsidiary of Anhui Weiming Biopharmaceutical and part of the Sinobioway Group, the company operates within the Weiming Pharmaceutical Industrial Park in the Hefei Chaohu Economic Development Zone. Its primary focus is on the development of monoclonal antibodies for autoimmune conditions, with a lead program being a biosimilar of adalimumab targeting TNF-alpha. The company leverages the group's large-scale manufacturing capabilities and R&D platforms to advance its pipeline. Founded in 2016, it has attracted investment from regional funds and strategic partners such as Pianzaihuang.